Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a large increase in short interest in June. As of June 30th, there was short interest totaling 44,712 shares, an increase of 102.3% from the June 15th total of 22,107 shares. Based on an average daily trading volume, of 25,828 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.1% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock traded up $0.03 during trading hours on Thursday, hitting $0.69. 2,978 shares of the stock were exchanged, compared to its average volume of 56,539. The stock has a market capitalization of $28.10 million, a P/E ratio of -0.52 and a beta of -0.41. The business’s 50-day moving average is $0.67 and its two-hundred day moving average is $0.66. Barinthus Biotherapeutics has a 12 month low of $0.51 and a 12 month high of $2.91.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its earnings results on Thursday, April 30th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.14.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Baird Financial Group Inc. grew its holdings in Barinthus Biotherapeutics by 108.2% during the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after acquiring an additional 100,000 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Barinthus Biotherapeutics by 115.8% in the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after acquiring an additional 76,800 shares during the last quarter. Finally, Rangeley Capital LLC lifted its position in shares of Barinthus Biotherapeutics by 88.8% during the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after purchasing an additional 75,024 shares in the last quarter. 25.20% of the stock is owned by institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.